博拓生物(688767) - 2024 Q4 - 年度业绩预告

Financial Performance Expectations - The company expects a net profit attributable to shareholders of approximately 170 million yuan for 2024, an increase of about 63.39 million yuan, representing a year-on-year growth of approximately 59.47%[3] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is approximately 119 million yuan, an increase of about 39.57 million yuan, representing a year-on-year growth of approximately 49.83%[3] - In 2023, the net profit attributable to shareholders was 106.61 million yuan, and the net profit after deducting non-recurring gains and losses was 79.43 million yuan[4] Market Expansion and Revenue Growth - The company has effectively captured customer demand and actively expanded both domestic and international markets, leading to steady growth in sales revenue[5] - The termination of overseas customer orders for COVID-19 testing products in 2024 will convert 5 million USD in advance payments and collected shipping fees into revenue, contributing to the increase in net profit[6] Investment Risks - The financial data in this earnings forecast has not been audited by a registered accountant, and investors are advised to pay attention to investment risks[7][8]